Lifetime Risk of Coronary Heart Disease by Cholesterol

Archives of Internal Medicine

163, 1966

Citation Report

#	ARTICLE	IF	CITATIONS
1	Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal of Geriatric Cardiology, 2003, 12, 357-360.	0.7	9
2	Framingham risk score and prediction of lifetime risk for coronary heart disease. American Journal of Cardiology, 2004, 94, 20-24.	0.7	440
3	Assessing coronary heart disease risk with traditional and novel risk factors. Clinical Cardiology, 2004, 27, 7-11.	0.7	39
4	Cholesterol Metabolism Is Affected by Calcium Phosphate Supplementation in Humans. Journal of Nutrition, 2005, 135, 1678-1682.	1.3	92
5	Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation, 2006, 113, 791-798.	1.6	1,072
6	Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Canadian Journal of Cardiology, 2006, 22, 913-927.	0.8	271
7	What is the role of angiotensin-receptor blockade in cardiovascular protection?. American Heart Journal, 2006, 152, 859.e1-859.e8.	1.2	4
8	The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis, 2006, 185, 12-20.	0.4	21
9	Serum fatty acids as biomarkers of fat intake predict serum cholesterol concentrations in a population-based survey of New Zealand adolescents and adults. American Journal of Clinical Nutrition, 2006, 83, 887-894.	2.2	26
10	Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. Current Opinion in Lipidology, 2006, 17, 619-625.	1.2	34
11	Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 98, 751-753.	0.7	8
12	Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (≥12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery. American Journal of Cardiology, 2006, 98, 1419-1423.	0.7	19
13	Risk factors for cardiovascular disease and hormone therapy in women. Heart, 2006, 92, iii24-iii28.	1.2	12
14	A 39-Year-Old Woman With Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2006, 296, 319.	3.8	0
15	Estimating Lifetime Risk of Developing High Serum Total Cholesterol: Adjustment for Baseline Prevalence and Single-Occasion Measurements. American Journal of Epidemiology, 2006, 165, 464-472.	1.6	11
16	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. BMJ: British Medical Journal, 2007, 334, 982-982.	2.4	16
17	Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 879-887.	1.7	77
18	Survey of Physician's Attitudes and Practices toward Lipid-Lowering Management Strategies. Cardiology, 2007, 107, 302-306.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Predicted risk of coronary heart disease among persons with type 2 diabetes. Coronary Artery Disease, 2007, 18, 595-600.	0.3	8
20	Cardiovascular Disease and Metabolic Risk Factors in Male Patients With Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder. Psychosomatics, 2007, 48, 412-417.	2.5	95
21	Impact of adherence to statins on coronary artery disease in primary prevention. British Journal of Clinical Pharmacology, 2007, 63, 698-708.	1.1	86
22	Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Preventive Medicine, 2008, 47, 619-623.	1.6	67
23	Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation, 2008, 118, 672-677.	1.6	90
24	Using Hypothetical Data to Assess the Effect of Numerical Format and Context on the Perception of Coronary Heart Disease Risk. American Journal of Health Promotion, 2008, 22, 291-296.	0.9	23
25	Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels. Circulation: Cardiovascular Genetics, 2009, 2, 354-361.	5.1	78
26	Prevalence and Progression of Subclinical Atherosclerosis in Younger Adults With Low Short-Term but High Lifetime Estimated Risk For Cardiovascular Disease. Circulation, 2009, 119, 382-389.	1.6	271
28	Short-term versus lifetime risk assessment for cardiovascular disease: Pros, cons, and clinical implications. Current Cardiovascular Risk Reports, 2009, 3, 144-149.	0.8	4
29	Impact of better adherence to statin agents in the primary prevention of coronary artery disease. European Journal of Clinical Pharmacology, 2009, 65, 1013-1024.	0.8	91
30	Changing trends (1986â€"2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: A community-based perspective. International Journal of Cardiology, 2009, 132, 66-74.	0.8	5
31	Predicting the 30-Year Risk of Cardiovascular Disease. Circulation, 2009, 119, 3078-3084.	1.6	688
32	Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting. Value in Health, 2010, 13, 87-94.	0.1	53
33	Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. Journal of Lipid Research, 2010, 51, 3342-3349.	2.0	41
34	Cardiovascular Risk Prediction. Circulation, 2010, 121, 1768-1777.	1.6	591
35	What Is the Lifetime Risk of Physician-diagnosed Asthma in Ontario, Canada?. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 337-343.	2.5	62
36	Earlier Intervention in the Management of Hypercholesterolemia. Journal of the American College of Cardiology, 2010, 56, 627-629.	1.2	39
37	The importance of HDL-C and CRP in cardiovascular risk evaluation in longevous elderly individuals. Einstein (Sao Paulo, Brazil), 2011, 9, 397-403.	0.3	8

#	ARTICLE	IF	CITATIONS
38	Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients. European Journal of Medical Research, 2011, 16, 85.	0.9	5
39	Synergistic effect of coronary artery disease risk factors on long-term survival in patients with normal exercise SPECT studies. Journal of Nuclear Cardiology, 2011, 18, 207-214.	1.4	31
40	Is Universal Pediatric Lipid Screening Justified?. JAMA - Journal of the American Medical Association, 2012, 307, 259-60.	3.8	56
41	Lifetime risk for cancer death by sex and smoking status: the lifetime risk pooling project. Cancer Causes and Control, 2012, 23, 1729-1737.	0.8	10
42	The Case for Treating Hypercholesterolemia at an Earlier Age. Journal of the American College of Cardiology, 2012, 60, 2640-2642.	1.2	19
43	Lifetime Risks of Cardiovascular Disease. New England Journal of Medicine, 2012, 366, 321-329.	13.9	780
44	Inverse Associations Between Perceived Racism and Coronary Artery Calcification. Annals of Epidemiology, 2012, 22, 183-190.	0.9	20
45	Comorbidity Cohort (2C) study: Cardiovascular disease severity and comorbid osteoarthritis in primary care. BMC Health Services Research, 2012, 12, 295.	0.9	13
46	Implementation of permutation testing to determine clustering of social and behavioral risk factors for coronary heart disease, National Health and Nutrition Examination Survey 2001â€"2004. Annals of Epidemiology, 2013, 23, 381-387.	0.9	2
47	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Journal of Clinical Lipidology, 2013, 7, 561-565.	0.6	147
48	Lifetime risk of developing coronary heart disease in Aboriginal Australians: a cohort study. BMJ Open, 2013, 3, e002308.	0.8	10
49	Prevalence of risk factors at presentation and early mortality in patients aged 80 years or older with ST-segment elevation myocardial infarction. Vascular Health and Risk Management, 2014, 10, 683.	1.0	12
50	Social and Behavioral Risk Marker Clustering Associated with Biological Risk Factors for Coronary Heart Disease: NHANES 2001â€"2004. BioMed Research International, 2014, 2014, 1-13.	0.9	6
51	The 2013 American College of Cardiology/American Heart Association Guidelines on Treating Blood Cholesterol and Assessing Cardiovascular Risk. Endocrinology and Metabolism Clinics of North America, 2014, 43, 869-892.	1.2	5
52	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. Journal of Clinical Lipidology, 2014, 8, 29-60.	0.6	289
53	Modifiable risk factors in periodontitis: at the intersection of aging and disease. Periodontology 2000, 2014, 64, 7-19.	6.3	142
54	Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. International Journal of Epidemiology, 2015, 44, 1800-1813.	0.9	269
55	Epidemiology of Blood Lipids and Lipoproteins. Contemporary Endocrinology, 2015, , 13-24.	0.3	1

#	ARTICLE	IF	CITATIONS
56	Perspectives on Cholesterol Guidelines. Contemporary Endocrinology, 2015, , 313-327.	0.3	0
57	Do statins prevent Alzheimer's disease? A narrative review. European Journal of Internal Medicine, 2015, 26, 666-669.	1.0	30
59	Lifetime Risk for Sudden Cardiac Death in the Community. Journal of the American Heart Association, 2016, 5, .	1.6	69
60	Recent Update to the US Cholesterol Treatment Guidelines. Circulation, 2016, 133, 1795-1806.	1.6	89
61	Long-Term Prognosis After Coronary Artery Calcium Scoring Among Low-Intermediate Risk Women and Men. Circulation: Cardiovascular Imaging, 2016, 9, e003742.	1.3	71
62	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. Scientific Reports, 2017, 7, 8422.	1.6	15
63	A Simple Community-Based Risk-Prediction Score for Sudden Cardiac Death. American Journal of Medicine, 2018, 131, 532-539.e5.	0.6	22
64	Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology, 2018, 11, 259-278.	1.3	7
65	Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia. Atherosclerosis, 2019, 290, 80-86.	0.4	11
66	Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines. Journal of Clinical Lipidology, 2019, 13, 356-359.	0.6	8
67	70-year legacy of the Framingham Heart Study. Nature Reviews Cardiology, 2019, 16, 687-698.	6.1	143
68	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	1.2	1,550
69	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
70	Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding. Journal of Lipid Research, 2019, 60, 516-527.	2.0	10
71	Hypercholesterolemia and Lifetime Risk of Coronary Heart Disease in the General Japanese Population: Results from the Suita Cohort Study. Journal of Atherosclerosis and Thrombosis, 2020, 27, 60-70.	0.9	9
72	Mildly Abnormal Lipid Levels, but Not High Lipid Variability, Are Associated With Increased Risk of Myocardial Infarction and Stroke in "Statin-Naive" Young Population A Nationwide Cohort Study. Circulation Research, 2020, 126, 824-835.	2.0	27
73	Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: A nationwide cohort study. European Journal of Preventive Cardiology, 2020, 27, 870-881.	0.8	31
74	Cardiovascular Disease Risk Assessment: Insights from Framingham. Global Heart, 2013, 8, 11.	0.9	200

#	ARTICLE	IF	CITATIONS
75	Lipids and Vascular Disease: A Framingham Perspective. Global Heart, 2013, 8, 25.	0.9	11
76	Performance of commercially-available cholesterol self-tests. Annals of Clinical Biochemistry, 2021, 58, 000456322199239.	0.8	2
77	Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk. EBioMedicine, 2021, 67, 103371.	2.7	5
78	Effect of Moderately but Persistently Elevated Lipid Levels on Risks of Stroke and Myocardial Infarction in Young Korean Adults. Journal of the American Heart Association, 2021, 10, e020050.	1.6	7
79	Framingham Heart Study. Journal of the American College of Cardiology, 2021, 77, 2680-2692.	1.2	35
80	Data storytelling is not storytelling with data: A framework for storytelling in science communication and data journalism. Information Society, 2021, 37, 312-322.	1.7	9
81	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4
82	The Effects of Dietary Taurine Supplementation on Plasma and Liver Lipid in Ovariectomized Rats. Advances in Experimental Medicine and Biology, 2009, 643, 389-395.	0.8	3
84	Undernutrition: diagnosis, causes, consequences and treatment. , 2009, , 153-168.		2
85	Associations of Serum Lipid Profiles with Incidence of Ischemic Heart Diseases in Korean Adults: Retrospective Cohort Study. Journal of the Korea Academia-Industrial Cooperation Society, 2012, 13, 2219-2231.	0.0	4
86	The Multifactorial Model of Cardiovascular Pathology. , 2006, , 93-131.		0
87	Management of Elevated Low-Density Lipoprotein Cholesterol. Fundamental and Clinical Cardiology, 2006, , 255-294.	0.0	0
88	Risk Factors for Cardiovascular Disease and the Framingham Study Equation. Fundamental and Clinical Cardiology, 2006, , 1-18.	0.0	0
89	Coronary Risk Factors: An Overview. , 2007, , 2609-2630.		3
90	Risk Factors for Cardiovascular Disease and the Framingham Study Equation. , 2007, , 1-18.		0
91	Cardiovascular Risk Assessment. , 2011, , 1-11.		0
92	Atherosclerosis: Basic Principles and Medical Management. , 2011, , 1-24.		0
94	Comparison of Patients with Acute Myocardial Infarction According to Age. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2019, 73, 23.	0.4	7

#	Article	IF	Citations
95	Cardiovascular Disease in Women: Focus on Lipid Management. Contemporary Cardiology, 2021, , 467-487.	0.0	0
96	The Prebiotic Effects of Oats on Blood Lipids, Gut Microbiota, and Short-Chain Fatty Acids in Mildly Hypercholesterolemic Subjects Compared With Rice: A Randomized, Controlled Trial. Frontiers in Immunology, 2021, 12, 787797.	2.2	30
97	Canadian Society of Clinical Chemists Harmonized Clinical Laboratory Lipid Reporting Recommendations on the Basis of the 2021 Canadian Cardiovascular Society Lipid Guidelines. Canadian Journal of Cardiology, 2022, 38, 1180-1188.	0.8	17
98	The association between blood PFAS concentrations and clinical biochemical measures of organ function and metabolism in participants of the Canadian Health Measures Survey (CHMS). Science of the Total Environment, 2022, 827, 153900.	3.9	28
101	The prognostic value of normal myocardial perfusion spect with positive coronary angiography. Nuclear Medicine Review, 2012, 15, 22-25.	0.3	3
102	Clinical associations between exercise and lipoproteins. Current Opinion in Lipidology, 2022, 33, 364-373.	1.2	2
103	Cardiovascular Risk Assessment and Management for Pediatricians. Pediatrics, 2022, 150, .	1.0	2
104	The associations between exercise and lipid biomarkers. Progress in Cardiovascular Diseases, 2022, 75, 59-68.	1.6	12
105	Prediction of hypercholesterolemia using machine learning techniques. Journal of Diabetes and Metabolic Disorders, 0, , .	0.8	1
106	Label-free and selective cholesterol detection based on multilayer functional structure coated fiber fabry-perot interferometer probe. Analytica Chimica Acta, 2023, 1252, 341051.	2.6	6
107	Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians. Acta Medica Bulgarica, 2023, 50, 19-26.	0.0	0
109	Updated Clinical Guide to Exercise and Lipids. , 2024, , 132-140.e2.		0